Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
169 USD | +0.54% | +1.18% | -14.35% |
May. 08 | HSBC Adjusts Price Target on Zoetis to $225 From $230 | MT |
May. 06 | BNP Paribas Exane Adjusts Price Target on Zoetis to $232 From $237 | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 30.87 times its estimated earnings per share for the ongoing year.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is highly valued given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-14.35% | 77.13B | B+ | ||
+14.09% | 8.4B | B- | ||
-0.70% | 3.22B | B- | ||
+14.70% | 1.64B | - | ||
-10.12% | 1.5B | B | ||
-22.60% | 1.3B | C- | ||
-4.20% | 1.25B | - | ||
-10.26% | 1.18B | - | ||
+5.06% | 1.1B | - | ||
-12.05% | 950M | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- ZTS Stock
- Ratings Zoetis Inc.